Top-Rated StocksTop-RatedNASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free MIRM Stock Alerts $25.56 +0.26 (+1.03%) (As of 09:50 AM ET) Add Compare Share Share Today's Range$25.19▼$25.7950-Day Range$23.57▼$28.1752-Week Range$23.14▼$35.56Volume13,333 shsAverage Volume526,671 shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$49.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Mirum Pharmaceuticals alerts: Email Address Mirum Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.10 Rating ScoreUpside/Downside96.6% Upside$49.73 Price TargetShort InterestBearish18.04% of Shares Sold ShortDividend StrengthN/ASustainability-1.69Upright™ Environmental ScoreNews Sentiment0.41Based on 8 Articles This WeekInsider TradingBalancedInsiders Both Buying and SellingProj. Earnings GrowthGrowingFrom ($1.39) to $0.12 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.51 out of 5 starsMedical Sector98th out of 918 stocksPharmaceutical Preparations Industry34th out of 427 stocks 4.6 Analyst's Opinion Consensus RatingMirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMirum Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mirum Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.04% of the outstanding shares of Mirum Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently decreased by 0.93%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirum Pharmaceuticals has received a 61.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirum Pharmaceuticals is -1.69. Previous Next 3.0 News and Social Media Coverage News SentimentMirum Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Mirum Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest10 people have searched for MIRM on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows24 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $101,200.00 in company stock and sold $111,017.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.Percentage Held by Insiders22.87% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Mirum Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.39) to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mirum Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.Click here to sign up for our free report & newsletter About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Read More MIRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIRM Stock News HeadlinesMay 18 at 9:17 AM | finance.yahoo.comMirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual MeetingMay 18 at 7:00 AM | businesswire.comMirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual MeetingMay 14, 2024 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) PT Lowered to $53.00 at Morgan StanleyMay 13, 2024 | finance.yahoo.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call TranscriptMay 13, 2024 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Receives Overweight Rating from Cantor FitzgeraldMay 13, 2024 | americanbankingnews.comHC Wainwright Comments on Mirum Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:MIRM)May 13, 2024 | americanbankingnews.comMirum Pharmaceuticals' (MIRM) "Buy" Rating Reaffirmed at HC WainwrightMay 13, 2024 | americanbankingnews.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Forecasted to Post Q2 2024 Earnings of $0.06 Per ShareMay 10, 2024 | finance.yahoo.comMirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net LossMay 10, 2024 | businesswire.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | markets.businessinsider.comPositive Outlook for Mirum Pharmaceuticals with Buy Rating Amid Upcoming Catalysts and Robust FinancialsMay 10, 2024 | markets.businessinsider.comMirum Pharmaceuticals: Strong Buy Recommendation Amidst Resilient Performance and Promising Clinical ProspectsMay 9, 2024 | markets.businessinsider.comBuy Rating for Mirum Pharmaceuticals Amidst Strong Sales and Promising Drug PipelineMay 9, 2024 | finance.yahoo.comQ1 2024 Mirum Pharmaceuticals Inc Earnings CallMay 9, 2024 | finance.yahoo.comMirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...May 8, 2024 | finance.yahoo.comMirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | finance.yahoo.comMirum Pharmaceuticals to Present at the Citizens JMP Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comMirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFICMay 1, 2024 | businesswire.comMirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024April 26, 2024 | investing.comMirum Pharmaceuticals Inc (MIRM)April 22, 2024 | seekingalpha.comMirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive ValueApril 18, 2024 | msn.comStifel starts Mirum at buy, cites IBATi drug potentialApril 17, 2024 | msn.comStifel Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy RecommendationApril 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment BreakthroughsApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mirum Pharmaceuticals Amid Positive Clinical Trial OutlookSee More Headlines Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/21/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MIRM CUSIPN/A CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees264Year FoundedN/APrice Target and Rating Average Stock Price Target$49.73 High Stock Price Target$66.00 Low Stock Price Target$37.00 Potential Upside/Downside+96.6%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,410,000.00 Net Margins-69.67% Pretax Margin-70.16% Return on Equity-56.46% Return on Assets-19.61% Debt Debt-to-Equity Ratio1.31 Current Ratio3.68 Quick Ratio3.47 Sales & Book Value Annual Sales$224.00 million Price / Sales5.32 Cash FlowN/A Price / Cash FlowN/A Book Value$5.33 per share Price / Book4.75Miscellaneous Outstanding Shares47,133,000Free Float36,354,000Market Cap$1.19 billion OptionableOptionable Beta1.13 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Christopher Peetz (Age 45)CEO & Director Comp: $1.09MMr. Peter Radovich M.B.A. (Age 46)Ph.D., COO & President Comp: $732.15kDr. Pamela Vig Ph.D. (Age 53)Chief Scientific Officer & Head of Research Comp: $678.2kMs. Lara Longpre MBA (Age 54)MSC, Chief Development Officer Comp: $678.2kMr. Eric H. Bjerkholt M.B.A. (Age 64)Chief Financial Officer Andrew McKibbenVice President of Investor Relations and FinanceMr. Paul K. RossChief Compliance OfficerMs. Erin Campany (Age 56)Senior Vice President of Human Resources Dr. Ian Clements Ph.D. (Age 55)Consultant Comp: $649.1kMs. Vinita P. KumarSenior vice President of QualityMore ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLEnliven TherapeuticsNASDAQ:ELVNBelite BioNASDAQ:BLTEMannKindNASDAQ:MNKDProthenaNASDAQ:PRTAView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 704,659 shares on 5/16/2024Ownership: 5.871%Silvercrest Asset Management Group LLCBought 63,871 shares on 5/16/2024Ownership: 0.345%California State Teachers Retirement SystemSold 124,119 shares on 5/16/2024Ownership: 0.185%Price T Rowe Associates Inc. MDBought 432,824 shares on 5/15/2024Ownership: 3.390%Affinity Asset Advisors LLCBought 110,000 shares on 5/15/2024Ownership: 0.339%View All Insider TransactionsView All Institutional Transactions MIRM Stock Analysis - Frequently Asked Questions Should I buy or sell Mirum Pharmaceuticals stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MIRM shares. View MIRM analyst ratings or view top-rated stocks. What is Mirum Pharmaceuticals' stock price target for 2024? 10 analysts have issued 1 year price objectives for Mirum Pharmaceuticals' stock. Their MIRM share price targets range from $37.00 to $66.00. On average, they predict the company's share price to reach $49.73 in the next year. This suggests a possible upside of 96.6% from the stock's current price. View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts. How have MIRM shares performed in 2024? Mirum Pharmaceuticals' stock was trading at $29.52 on January 1st, 2024. Since then, MIRM stock has decreased by 14.3% and is now trading at $25.30. View the best growth stocks for 2024 here. When is Mirum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our MIRM earnings forecast. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.32. The company had revenue of $69.55 million for the quarter, compared to the consensus estimate of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative trailing twelve-month return on equity of 56.46%. What ETFs hold Mirum Pharmaceuticals' stock? ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Products ETF (BBP), Tema Cardiovascular and Metabolics ETF (HRTS) and First Trust Innovation Leaders ETF (ILDR) and What guidance has Mirum Pharmaceuticals issued on next quarter's earnings? Mirum Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $310.0 million-$320.0 million, compared to the consensus revenue estimate of $317.2 million. What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX). When did Mirum Pharmaceuticals IPO? Mirum Pharmaceuticals (MIRM) raised $75 million in an IPO on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Mirum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (5.87%), Vanguard Group Inc. (4.69%), Price T Rowe Associates Inc. MD (3.39%), William Blair Investment Management LLC (1.33%), Clearbridge Investments LLC (0.56%) and Rice Hall James & Associates LLC (0.46%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MIRM) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.